Amendment effect of resveratrol on diclofenac idiosyncratic toxicity: Augmentation of the anti-inflammatory effect by assessment of Arachidonic acid and IL-1β levels

Idiosyncratic drug induced liver injury (DILI) is one of the most serious hazards that could be induced due to the misuse of drugs. Diclofenac has long been well-known to prompt such complication. Resveratrol is one of the newest nutraceuticals that has been recently introduced in the medicinal field and proved to be effective in ameliorating many types of drug-induced hepatic injuries. The present study aimed to assess if combining resveratrol with diclofenac would result in hepato-protection and/or synergistic anti-inflammatory effect in an acute carrageenan induced paw edema model in rats. Results revealed that the combination groups showed augmented anti-inflammatory effect represented by decreased levels of interleukin-1β and arachidonic acid. Furthermore; combination groups diminished the inflammation-induced oxidative stress and nitrosative stress as shown in the reduction of GSSG/GSH ratio, MDA and NOX levels. Moreover; combination groups also prevented the elevation in liver enzymes namely AST and ALT. In conclusion we can say that addition of resveratrol to diclofenac tablets could be beneficial for patients suffering from serious liver conditions.